Cite

    Eso, Y. et al. (2020). Branched‐chain amino acid to tyrosine ratio is an essential pre‐treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma. Journal of hepato-biliary-pancreatic sciences. pp. 913-921. [Online].